Prostaglandins and cancer: A review of tumor initiation through tumor metastasis

Prostaglandins

Volumn 21, Issue 5, 1981, Pages 833-864

  Honn, Kenneth V ^a   Bockman, Richard S ^b   Marnett, Lawrence J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; BENZO[A]PYRENE DERIVATIVE; CARCINOGEN; DNA; MUTAGENIC AGENT; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D; PROSTAGLANDIN E; PROSTAGLANDIN F; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE A2;

ANIMAL; CELL DIFFERENTIATION; CELL DIVISION; CELL TRANSFORMATION; CYTOLOGY; DRUG EFFECT; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; IATROGENIC DISEASE; KIDNEY; MALE; METABOLISM; METASTASIS; NEOPLASM; OXIDATION REDUCTION REACTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SKIN;

ANIMAL; BENZO(A)PYRENE; BENZOPYRENES; CARCINOGENS; CELL DIFFERENTIATION; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE INHIBITORS; DNA; EPOPROSTENOL; FEMALE; HEMATOPOIETIC STEM CELLS; HUMAN; KIDNEY; MALE; MUTAGENS; NEOPLASM METASTASIS; NEOPLASMS; OXIDATION-REDUCTION; PROSTAGLANDINS; PROSTAGLANDINS D; PROSTAGLANDINS E; PROSTAGLANDINS F; SKIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TETRADECANOYLPHORBOL ACETATE; THROMBOXANE A2;

EID: 0019566535     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/0090-6980(81)90240-9     Document Type: Article

References (161)

1. Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals: Discussion
2. Antioxidants and cancer. IV. Initiating activity of malonaldehyde as a carcinogen
3. Mutagenicity of malonaldehyde, a decomposition product of peroxidized polyunstaturated fatty acids
4. Comparison of the mutagenicities of malondialdehyde and the side products formed during its chemical synthesis
5. Carcinogenesis by chemicals: an overview — G.H.A. Clowes memorial lecture
6. Chemical carcinogenesis
7. Ultimate chemical carcinogens as reactive mutagenic electrophiles
8. Studies on the formation of protein-bound derivatives of 3:4-benzypyrene in epidermal fraction of mouse skin
9. 14C
10. Metabolic activation of benzo[alpyrene proceeds by a diol epoxide
11. Identification of mutagenic metabolites of benzo[a]pyrene in mammalian cells
12. Structure of benzo[a]pyrene-nucleic acid adducts formed in human and bovine bronchial explants
13. Tumorigenicity studies with diol-epoxides of benzo[a]pyrene which indicate that (±)-trans 7, 8 -dihydroxy-9, 10 -epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene is an ultimate carcinogen in newborn mice
14. Cooxygenation of organic substrates by the prostaglandin synthetase of sheep vesicular gland
15. Prostaglandin synthetase dependent benzo[a]pyrene oxidation: products of the oxidation and inhibition of their formation by antioxidants
16. Metabolism of benzo[a]pyrene to reactive intermediates via prostaglandin biosynthesis
17. Peroxidatic oxidation of benzo[a]pyrene and prostaglandin biosynthesis
18. Prostaglandin synthetase dependent activation of 7,8-dihydro-7,8-dihydroxy-benzo[a]pyrene to mutagenic derivatives
19. Arachidonic and dependent metabolism of 7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene by ram seminal vesicles
20. Arachidonic acid dependent metabolism of (±)-trans-7,8-dihydroxy-7,8-dihydro-benzo(a)pyrene (BP-7,8-diol) to 7,10/8,9 tetrols
21. Hydroperoxide-dependent oxygenation of trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene by ram seminal vesicles. Source of the oxygen
22. Differential distribution of mixed function oxidase activities in rabbit kidney
23. Co-oxidation of benzidine by renal medullary prostaglandin cyclooxygenase
24. Benzidine binding to nucleic acids mediated by the peroxidative activity of prostaglandin endoperoxide synthetase
25. Mechanism of FANFT co-oxidation by prostaglandin endoperoxide synthetase
26. Co-oxygenation by prostaglandin cyclooxygenase from rabbit inner medulla
27. A new, quantitative approach to the study of the stages of chemical carcinogenesis in the mouse skin
28. Tumor promoting activity of phorbol and four diesters of phorbol in mouse skin
29. Tumor-promoting agents in two-stage carcinogenesis
30. The early stimulation of phospholipid metabolism by 12-0-tetradecanoyl-phorbol-13-acetate and its specificity for tumor promotion
31. Induction of the polyamine-biosynthetic enzymes in mouse epidermis and their specificity for tumor promotion
32. Retinoid inhibition of superoxide anion radical production by human polymorphonuclear leukocytes stimulated with tumor promoters
33. Effects of phorbol-12,13-diesters on prostaglandin production and phospholipase activ́ity in canine kidney (MDCK) cells
34. Inflammatory, tumor initiating and promoting activities of polycyclic aromatic hydrocarbons and diterpene esters in mouse skin as compared with their prostaglandin releasing potency in vitro
35. Prostaglandins and skin tumor promotion: inhibition of tumor promoter-induced ornithine decarboxylase activity by inhibitors of prostaglandin synthesis
36. 2 in mouse epidermis in vivo
37. The effect of indomethacin on cell proliferation induced by chemical and mechanical means in mouse epidermis in vivo
38. Epidermal prostaglandins after topical application of a tumor promoter
39. Prostaglandin E and F levels in mouse epidermis are increased by tumor-promoting phorbol esters
40. Inhibition by prostaglandin synthesis inhibitors of the induction of epidermal ornithine decarboxylase activity, the accumulation of prostaglandins, and tumor promotion caused by 12-0-tetradecanoyl phorbol-13-acetate
41. Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats
42. Tumor growth and response to treatment: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen
43. Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice
44. Indomethacin enhancement of TPA tumor promotion in mice
45. Enhancement of carcinogenesis by prostaglandins
46. Role of cyclic AMP and protein kinase on the steroidogenic action of ACTH, prostaglandin E, and dibutyryl cyclic AMP in normal adrenal cells and adrenal tumor cells from humans
47. Human lymphocyte metabolism: effects of cyclic and non cyclic nucleotides on stimulation by phytohemagglutinin
48. Inhibition of tumor growth in vivo and in vitro by prostaglandin E.
49. The relationship between concentration of prostaglandin E and rates of cell replication
50. 2 production inhibits proliferation of polyoma virus-transformed 3T3 cells: correlation with cellular levels of cyclic AMP
51. 2α
52. 2α and rates of cell proliferation
53. 2 in Yoshida hepatoma and the inhibition of tumor growth by non-steroidal anti-inflammatory drugs
54. Prostaglandin E modulation of the mitogenic response of human T-cells
55. 2 α on the growth of a hormone dependent rat mammary tumor
56. Evidence that prostaglandins do not have a role in the cytostatic action of anti inflammatory drugs
57. Indomethacin in submicromolar concentrations inhibits cyclic AMP-dependent protein kinase
58. 2. A new model for the hypercalcemia of cancer
59. Prostaglandin production by mouse fibrosarcoma cells in culture: inhibition by indomethacin and aspirin
60. The growth of mouse bone marrow cells in vitro
61. Behavior on transfer of serum stimulated bone marrow colonies
62. Purification and properties of human urinary colony stimulating factor (CSF)
63. Factors regulating macrophage production and growth
64. Purification and characterization of the in vitro colony forming cell in monkey hematopoietic tissue
65. In vitro production of colony stimulating activity. I. Exposure of mouse peritoneal cells to endotoxin
66. Modulation of hemopoiesis by prostaglandins
67. Limitation of excessive myelopoiesis by the extrinsic modulation of macrophage derived prostaglandin E
68. Role for monocyte-macrophage derived colony stimulating factor and prostaglandin E in positive and negative feedback control of myeloid stem cell proliferation
69. Induction of prostaglandin E synthesis in normal and neoplastic macrophages: A new role for colony stimulating factor(s)
70. Modulation of granulopoiesis: opposing roles of prostaglandin F and E
71. Regulation of human myelopoiesis by prostaglandin E and lactoferrin
72. Prostaglandin production by human blood monocytes and mouse peritoneal macrophages: synthesis dependent on in vitro culture conditions
73. Regulation of macrophage and granulocyte proliferation: specifities of prostaglandin E and lactoferrin
74. Limitation of macrophage production in long-term marrow cultures containing prostaglandin E
75. Differentiation of a cell line in myeloid leukemia
76. Inhibition of differentiation of cultured mouse myeloid leukemia cells by nonsteroidal anti inflammatory agents and counteraction of the inhibition by prostaglandin E
77. Regulation of prostaglandin synthesis during differentiation of cultured mouse myeloid leukemia cells
78. Humoral modulation of human acute myelogenous leukemia cell growth in vitro
79. Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL-60) by compounds which induce differentiation of murine leukemia cells
80. Insensitivity of chronic myeloid leukemia cells to inhibition of growth by prostaglandin E
81. Abnormal responsiveness of granulocyte-macrophage committed colony-forming cells from patients with chronic myeloid leukemia to inhibition by prostaglandin E
82. Prostaglandin E inhibition of T-lymphocyte colony formation: a possible mechanism of monocyte modulation of clonal expansion
83. Prostaglandin producing suppressor cells in Hodgkin°s disease
84. Stage-dependent reduction in T colony formation in Hodgkin°s Disease
85. 2 α on the growth of leukemia cells in culture
86. Inhibition of lymphoma cell proliferation by supernatant from fibrosarcoma cultures: preliminary evidence that the inhibitory material is prostaglandin E
87. 1 or cyclic 3°,5°-AMP
88. Stimulation of erythropoiesis in plethoric mice by prostaglandins and its inhibition by anti erythropoietin
89. Erythroleukemic differentiation
90. 1 induces differentiation in Friend erythroleukemia cells
91. Effect of endogenous and exogenous PGE on Friend erythroleukemia cell growth and differentiation
92. Morphological differentiation induced by prostaglandins in mouse neuroblastoma cells in culture
93. 2 sur la proliferation et la differenciation morphologique d°une lignee cellulaire de neuroblastome murin
94. 1 and papavarine
95. Induction of abnormal development and differentiation in cultured mammary glands cyclic adenine nucleotide and prostaglandins
96. Effects of indomethacin on Moloney sarcoma virus-induced tumors
97. Alteration of tumor growth by aspirin and Indomethacin: Studies with two transplantable tumors in mouse
98. Breast cancer and prostaglandins: A new approach to treatment
99. Prostaglandin synthesis inhibition: Effect on bone changes in sarcoma in BALB/c mice
100. Cancer growth, response to treatment and survival time in mice: Beneficial effect of the prostaglandins synthesis inhibitor flurbiprofen
101. Mechanism of inhibition of tumor by aspirin and indomethacin
102. Subversion of immune system by tumor cells and role of prostaglandins
103. The effect of 5,8,11,14-eicosatetraynoic acid on lipid metabolism
104. Influence of prostaglandin analogues on epithelial cell proliferation and xenograft growth
105. Enhancement of anti-cancer activity of cytotoxic chemotherapy with protection of normal tissues by inhibition of P.G. synthesis
106. The inhibition by aspirin and indomethacin of osteolytic tumor deposit and hypercalcaemia in rats with Walker tumors and its possible application to human breast cancer
107. Successful treatment of hypercalcaemia by indomethacin in mice bearing a prostaglandin-producing fibrosacroma
108. 2 carcinoma model in the rabbit
109. 2 carcinoma: Effects of hydrocorticosone and indomethancin
110. The interactions between indomethacin and cytotoxic drugs in mice bearing B-16 melanomas
111. 2
112. 2
113. 2
114. 1 inhibition of chondrosarcoma growth
115. 2: Comparison with chemotherapeutic agents
116. 1 on the immune response in B-16 melanoma mice
117. A pathobiologic overview of metastasis
118. Mechanisms and prevention of cancer dissemination: An overview
119. Mechanisms of metastasis
120. Systemic cancer and the metastatic process
121. Breast cancer, prostaglandins, bone metastasis
122. Prostaglandins and breast cancer
123. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells
124. Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers
125. Prostaglandins from tumors of human large bowel
126. 2 and cyclic AMP levels in human breast tumors
127. Prostaglandins and metastasis
128. 2 levels in human breast carcinoma
129. Macrophages in syngeneic animal tumors
130. The macrophage content of some human tumors
131. Detection and quantitation of macrophage infiltration into primary human tumors with the use of cell surface markers
132. Content and distribution of macrophages and lymphocytes in solid malignant human tumors
133. Regulation of prostaglandin synthesis and of the selective release of lysosomal hydrolases by mouse peritoneal macrophages
134. Prostaglandin-like material extracted from squamous carcinomas of the head and neck
135. Increased prostaglanding synthesis by macrophages from tumor bearing mice
136. 2 by tumor cells in vitro
137. Elevated prostaglandin synthetase activity in methylcholanthrene-transformed mouse BALB/3T3
138. 2 formation by malignant melanoma cells correlates inversely with cellular metastatic potential
139. Arachidonic acid metabolism by rat chloroleukemia cells in culture
140. 2) activity by Lewis Lung carcinoma (3LL) cells
141. Platelet-tumor cell interactions in mice. The role of platelets in the spread of malignant disease
142. Thrombogenic activity of mouse and human tumors: Effects on platelets, coagulation, and fibrinolysis, and possible significance for metastasis
143. Increasing the efficiency of cancer chemotherapy with heparin “Clinical Study”
144. The Inhibitory effect of heparin and warfarin treatments on the intravascular survival of B-16 melanoma cells in syngeneic C57 mice
145. Neutral proteinase inhibitors and antimetastatic effects in mice
146. Platelet-cancer cell interaction in metastasis formation: A possible therapeutic approach to metastasis prophylaxix
147. 2 and prostacyclin
148. Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin
149. The influence of platelet aggregation inhibitors on metastasis formation in mice
150. General considerations for the studies of experimental cancer metastasis
151. 2 controls pulmonary metastasis of malignant melanoma cells
152. Trusseauδs Syndrome and other manifestations of chronic disseminated coagulopathy in patientswith neoplasms: Clinical, pathophysiological and therapeutic features
153. Thromboxane synthetase inhibitors and prostacyclin can control tumor cell metastasis
154. 2